<DOC>
	<DOCNO>NCT02677805</DOCNO>
	<brief_summary>The aim study assess efficacy safety BoNT/a-DP treatment glabellar line comparison placebo , include efficacy repeat treatment long term safety .</brief_summary>
	<brief_title>Botulinum Toxin Treatment Glabellar Lines : Efficacy Safety Study II</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Aged â‰¥ 18 year old time screening Has moderate severe glabellar frown line maximum frown ( severity score 2 3 FWS ) determine inclinic assessment investigator subject ( : 0= 'none ' , 1= 'mild ' , 2= 'moderate ' , 3= 'severe ' ) . Any medical condition may place subject increase risk due exposure botulinum toxin , include diagnose myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , profound atrophy weakness target muscle , condition ( investigator 's discretion ) might interfere neuromuscular function contraindicate botulinum toxin therapy . Previous treatment serotype botulinum toxin indication within 12 month prior screen , plan treatment botulinum toxin serotype reason trial ( investigational treatment ) . Active skin disease/infection irritation treatment area . Pregnant , breastfeed plan become pregnant trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>